7/15/2013 7:09:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Buying Alexion Pharmaceuticals Inc would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drugmaker is ultimately not willing to pay. Two people familiar with the matter have told Reuters that the Basel-based firm is seeking financing for a potential bid for Alexion, which specialises in the treatment of rare diseases. The sky-high prices and lower development and marketing costs of treatments for orphan diseases are increasingly drawing the attention of big pharmaceutical companies as their older drugs lose patent protection. A bid for Alexion would mark an attempt by Roche to diversify beyond its core cancer competencies through acquisitions, following a string of failures from its own research operations for drugs to treat cardio metabolic diseases.
Help employers find you! Check out all the jobs and post your resume.
comments powered by